Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 18/20 | 0.84 |
| ▸ | CCNA2 | P20248 | 16/20 | 0.84 |
| ▸ | CDK2 | P24941 | 16/20 | 0.84 |
| ▸ | CCNA1 | P78396 | 16/20 | 0.84 |
| ▸ | PLK3 | Q9H4B4 | 11/20 | 0.84 |
| ▸ | PLK2 | Q9NYY3 | 11/20 | 0.84 |
| ▸ | AURKA | O14965 | 8/20 | 0.84 |
| ▸ | TTK | P33981 | 5/20 | 0.84 |
| ▸ | CDK4 | P11802 | 1/20 | 0.63 |
| ▸ | CCND3 | P30281 | 1/20 | 0.63 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.63 |
| ▸ | IGF1R | P08069 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3502835 | 0.92 | PLK1 (1.00) | PLK1CCNA2CDK2CCNA1PLK3 | |
| SCHEMBL3505811 | 0.88 | PLK1 (0.78) | PLK1CCNA2CDK2CCNA1PLK3 | |
| SCHEMBL1560127 | 0.85 | TTK (1.00) | PLK1CCNA2CDK2CCNA1PLK3 | |
| SCHEMBL4154945 | 0.85 | CDK2 (1.00) | PLK1CCNA2CDK2CCNA1PLK3 | |
| SCHEMBL23855770 | 0.83 | CDK2 (0.84) | PLK1CCNA2CDK2CCNA1PLK3 | |
| SCHEMBL1559725 | 0.82 | TTK (0.81) | PLK1CCNA2CDK2CCNA1PLK3 | |
| SCHEMBL3504627 | 0.81 | PLK1 (1.00) | PLK1CCNA2CDK2CCNA1PLK3 | |
| SCHEMBL1889494 | 0.81 | TTK (0.79) | PLK1AURKATTKIGF1R | |
| SCHEMBL15378078 | 0.81 | TTK (0.91) | PLK1CCNA2CDK2CCNA1PLK3 | |
| SCHEMBL1559694 | 0.81 | PLK1 (0.59) | PLK1CCNA2CDK2CCNA1PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303891-B1 | PYRAZOLO-QUINAZOLINES AS PROTEIN KINASE ACTIVITY MODULATORS | SERVIER LAB (FR) | 2016-02-17 | — | — | EP | disclosed |
| US-8846701-B2 | Pyrazolo-quinazolines | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-09-30 | — | — | US | disclosed |
| US-20110105542-A1 | PYRAZOLO--QUINAZOLINES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105542-A1 | PYRAZOLO--QUINAZOLINES | PDXK, MAP4K5, MAP3K1 | PLK1 32/4885CCNA2 690/4885CDK2 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.